— Know what they know.
Not Investment Advice

VDRM OTC

ViaDerma, Inc.
1W: +100.0% 1M: +100.0% 3M: -50.0% YTD: -33.3% 1Y: +0.0% 3Y: -98.3% 5Y: -98.5%
$0.00
-0.00 (-50.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 58 · $123371 mcap · 126M float · 0.074% daily turnover · Short 84% of daily vol

Balance Sheet Trends

Total Assets
$1M +79.4% ▲
5Y CAGR: +86.7%
Total Liabilities
$1M -54.8% ▼
5Y CAGR: -16.1%
Shareholders Equity
$123K +106.7% ▲
Cash & Investments
$10K +1.7% ▲
5Y CAGR: +0.4%
Total Debt
$323K -22.2% ▼
5Y CAGR: -14.8%
Net Debt
$313K -22.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$10K$10K$12K$10K$10K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$10K$10K$12K$10K$10K
Net Receivables$16K$27K$261K$702K$1M
Inventory$41K$83K$0$0$0
Other Current Assets$0$0$0$0$0
Total Current Assets$66K$120K$273K$712K$1M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$3K$3K$2K$2K$2K
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$3K$3K$2K$2K$2K
Total Assets$69K$123K$275K$714K$1M
— Liabilities —
Accounts Payable$54K$35K$34K$12K$18K
Short-Term Debt$770K$589K$415K$415K$323K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$2M$2M$2M$697K
Total Current Liabilities$3M$2M$3M$3M$1M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$0$0$0$0
Total Liabilities$3M$2M$3M$3M$1M
— Equity —
Common Stock$72K$86K$98K$98K$123K
Retained Earnings-$12M-$12M-$14M-$14M-$14M
Accumulated OCI-$72K-$86K-$98K-$98K-$123K
Total Stockholders Equity-$3M-$2M-$2M-$2M$123K
Total Liabilities & Equity$69K$123K$275K$714K$1M
— Key Metrics —
Total Debt$770K$589K$415K$415K$323K
Net Debt$760K$578K$404K$405K$313K
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms